Hoth Therapeutics Secures Patent Allowance for HT-KIT Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 26 2026
0mins
Source: PRnewswire
- Patent Allowance Announcement: Hoth Therapeutics announced that its HT-KIT therapeutic has received a Notice of Allowance from the USPTO, covering antisense oligomers targeting MS4A6A pre-mRNA splicing, which is expected to enhance its market competitiveness in allergic and inflammatory diseases.
- Scientific Validation: CEO Robb Knie stated that this allowance serves as a significant validation of the science underlying their mast cell platform, further strengthening the intellectual property foundation of the HT-KIT program, which may drive future clinical research and product development.
- IND Submission Plans: Hoth expects to finalize its IND submission for the HT-KIT program in 2026, followed by first-in-human studies, which will lay the groundwork for innovative treatments in mast cell-driven diseases.
- Subsidiary Structure Adjustment: The company is exploring placing its biotechnology pipeline and therapeutic development projects under a separate wholly-owned subsidiary to preserve the value of its biotechnology portfolio while enabling the parent company to pursue emerging opportunities in AI semiconductor infrastructure.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
